Global Genitourinary Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Apr-2017
No. of pages: 500
Inquire Before Buying

"Delivery of this report will take 1-3 days after purchase."

The Global Genitourinary Partnering 2010 to 2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genitourinary Partnering 2010 to 2017 provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Genitourinary partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Genitourinary partnering agreement structure

Genitourinary partnering contract documents

Top Genitourinary deals by value

Most active Genitourinary dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genitourinary deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2010. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.

Report scope

Global Genitourinary Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.

Global Genitourinary Partnering 2010 to 2017 includes:

Trends in Genitourinary dealmaking in the biopharma industry since 2010

Analysis of Genitourinary deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Genitourinary deal contract documents

Comprehensive access to over 3500 Genitourinary deal records

The leading Genitourinary deals by value since 2010

Most active Genitourinary dealmakers since 2010

The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.

In Global Genitourinary Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genitourinary Partnering 2010 to 2017 report provides comprehensive access to available deals and contract documents for over 3500 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise Genitourinary rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Genitourinary Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Genitourinary deal trends since 2010

Access Genitourinary deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Genitourinary partner companies

Comprehensive access to over 750 links to actual Genitourinary deals entered into by the world's biopharma companies

Indepth review of Genitourinary deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Genitourinary opportunities

Uncover companies actively partnering Genitourinary opportunities

Global Genitourinary Partnering 2010-2017: Deal trends, players and financials

Table of Contents
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking
2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Genitourinary partnering by deal type
2.4. Genitourinary partnering by industry sector
2.5. Genitourinary partnering by stage of development
2.6. Genitourinary partnering by technology type
2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering
3.1. Introduction
3.2. Disclosed financials terms for Genitourinary partnering
3.3. Genitourinary partnering headline values
3.4. Genitourinary deal upfront payments
3.5. Genitourinary deal milestone payments
3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers
4.1. Introduction
4.2. Most active in Genitourinary partnering
4.3. List of most active dealmakers in Genitourinary
4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory
5.1. Introduction
5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genitourinary therapeutic target

Appendices

Appendix 1 - Directory of Genitourinary deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Genitourinary deals by deal type 2010 to 2017
Appendix 3 - Directory of Genitourinary deals by stage of development 2010 to 2017
Appendix 4 - Directory of Genitourinary deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Genitourinary partnering since 2010
Figure 2: Genitourinary partnering by deal type since 2010
Figure 3: Genitourinary partnering by industry sector since 2010
Figure 4: Genitourinary partnering by stage of development since 2010
Figure 5: Genitourinary partnering by technology type since 2010
Figure 6: Genitourinary partnering by indication since 2010
Figure 7: Genitourinary deals with a headline value
Figure 8: Genitourinary deals with upfront payment values
Figure 9: Genitourinary deals with milestone payment
Figure 10: Genitourinary deals with royalty rates
Figure 11: Active Genitourinary dealmaking activity- 2010 to 2017
Figure 12: Top Genitourinary deals by value since 2010
  • Global Peptide Therapeutics Sales Market Report 2017
    Published: 14-Aug-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Peptide Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Peptide Therapeutics for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - ......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market Research Report 2017
    Published: 14-Aug-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hypertrophic Cardiomyopathy Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North A......
  • Global Hypertrophic Cardiomyopathy Therapeutics Sales Market Report 2017
    Published: 11-Aug-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Hypertrophic Cardiomyopathy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Hypertrophic Cardiomyopathy Therapeutics for these regions, from 2012 to 2022 (forecast) , covering - United Stat......
  • United States Pain Management Therapeutics Market, Patients Volume, and 50 Company’s Pipeline Analysis (By Product, Indication, Phase of Development)
    Published: 09-Aug-2017        Price: US 1100 Onwards        Pages: 77
    The United States market for pain management therapeutics remains a substantial growth area for pharmaceutical companies, as they continue their efforts to maintain significant growth margins by tapping into markets of major unmet medical needs. United States Pain Therapeutics market persists with regular developments and discoveries of new drugs addressing pain related health ailment issue. The widespread availability of drugs and the advent of new drugs have accelerated the pace of growth i......
  • Global Acute Ischemic Stroke Therapeutics Market 2017-2021
    Published: 09-Aug-2017        Price: US 3500 Onwards        Pages: 84
    About Acute Ischemic Stroke Therapeutics AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of appro......
  • Crigler-Najjar Syndrome - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 36
    Crigler-Najjar Syndrome - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H2 2017, provides an overview of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape. Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Symptoms include yello......
  • Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 26
    Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sandhoff Disease (Jatzkewitz-Pilz Syndrome) - Pipeline Review, H2 2017, provides an overview of the Sandhoff Disease (Jatzkewitz-Pilz Syndrome) (Genetic Disorders) pipeline landscape. Sandhoff disease is an inherited lipid storage disorder that progressively destroys nerve cells (neurons) in t......
  • Familial Adenomatous Polyposis - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 37
    Familial Adenomatous Polyposis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis  (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. ......
  • Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017
    Published: 08-Aug-2017        Price: US 2000 Onwards        Pages: 41
    Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2017, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Genetic Disorders) pipeline landscape. Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs